SCNI Stock Stabilizes As Nasdaq Compliance Risk Fades

Scinai Immunotherapeutics Ltd. stocks have been trading up by 56.92 percent amid heightened optimism from its latest biotech developments.

Live Update At 07:47:29 EDT: On Tuesday, October 13, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 56.92%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI, Scinai Immunotherapeutics Ltd., just took a major regulatory risk off the table by regaining Nasdaq compliance on the $1.00 minimum bid rule. For active traders, that alone changes the trading landscape. A stock that was fighting delisting headlines now has room to trade more on fundamentals, catalysts, and momentum.

Recent price action shows exactly that tug-of-war. Over the past several weeks, SCNI has pulled back from the mid-$1.50s and $1.90s into the low $1.10–$1.30 range, with closes like $1.42, $1.41, $1.33, and most recently around $1.16–$1.22. That tells traders the initial compliance run may be cooling, but the floor near $1.10 is still holding for now.

More Breaking News

• RZLV Stock Slips As Traders Focus On Debt And Support
• BKYI Stock Rockets As Gulf Partnership And FIDO Win Ignite Momentum
• AIXI Stock Whipsaws As Traders Target Volatile AI Play
• FCHL Stock Draws Day Traders As Volatility Spikes

On the fundamentals side, Scinai Immunotherapeutics reported about $1.31M in revenue and trades around 1.2x sales. Book value per share sits near $1.83, while SCNI’s price-to-book ratio hovers around 0.64, meaning the market prices the stock at a discount to its stated equity. Returns on equity and assets are sharply negative, signaling a company still in heavy build-out and burn mode. For traders, SCNI is a classic speculative biotech: real assets, a small revenue base, weak profitability, and a chart that can move fast on headlines.

Why Traders Are Watching SCNI Now

Traders are watching SCNI closely because the biggest near-term threat — a Nasdaq delisting — has been pushed out of the picture. Scinai Immunotherapeutics locked in 19 consecutive trading days above $1.00, which brought it back into compliance with Nasdaq’s minimum bid requirement. That ended the formal delisting risk and closed the Nasdaq matter. When an overhang like that disappears, it often resets how day traders and swing traders frame the ticker.

Now the focus shifts to SCNI’s core story: its NanoAb immunology programs and its push to grow contract development and manufacturing organization (CDMO) operations. This dual track gives traders two potential sources of future catalysts. NanoAb data, new deals, or CDMO contracts can all spark momentum. SCNI is tiny in revenue terms, but it holds about $11.6M in total assets and some $1.66M in cash, with 31 employees and a solid equipment base. That’s enough infrastructure to matter, but still small enough that any material progress can move the needle.

The chart confirms SCNI’s potential for sharp, tradable swings. Intraday data shows wild spikes from roughly $1.10 premarket to highs above $3.30 in one session before fading back under $2.70. Those swings are a textbook example of what short-term traders look for — range, liquidity, and emotion. With Nasdaq compliance secured, more of that energy can flow into pure price discovery rather than fear of a forced delisting.

For now, Scinai Immunotherapeutics trades at a discount to book and is still losing money, but the compliance win stabilizes its platform. Short-term, that’s enough to keep SCNI firmly on many watchlists.

Conclusion

For traders who specialize in volatile small caps, SCNI checks several key boxes right now. Scinai Immunotherapeutics has removed an immediate existential threat by regaining full Nasdaq compliance on the $1.00 bid requirement. That alone lowers headline risk. It means fewer panic headlines about delisting and more room for Scinai’s NanoAb and CDMO narratives to drive SCNI’s tape.

At the same time, the numbers remind everyone that SCNI is not a safe, steady compounder. Scinai Immunotherapeutics is still deeply unprofitable, with negative returns on equity over -100% and heavy accumulated losses. Revenue of roughly $1.31M and an enterprise value under $10M make SCNI a micro-cap that can move quickly when volume hits. The discount to book value and the capital-intensive asset base add fuel for speculation, but none of this changes the risk profile.

This is exactly the kind of setup where chart discipline matters more than opinions. As Tim Sykes likes to tell traders, “The market doesn’t care about your beliefs, only your plan and your discipline.” That philosophy lines up closely with another key reminder for active traders: As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.”. SCNI rewards planning — mapping support near recent lows, watching for volume surges, and being ready to cut losses quickly if the story or price action cracks. For educational and research-focused traders, Scinai Immunotherapeutics is a live case study in how regulatory catalysts, tiny fundamentals, and big intraday ranges collide.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.